Malignant neoplasm of left ovary
ICD-10 C56.2 is a billable code used to indicate a diagnosis of malignant neoplasm of left ovary.
C56.2 refers to a malignant neoplasm specifically located in the left ovary. This condition is characterized by the uncontrolled growth of abnormal cells in the ovarian tissue, which can lead to the formation of tumors. Ovarian cancer is often asymptomatic in its early stages, making early detection challenging. Common symptoms may include abdominal bloating, pelvic pain, and changes in urinary habits. The diagnosis is typically confirmed through imaging studies, such as ultrasound or CT scans, and histopathological examination of biopsy samples. Staging of ovarian cancer is crucial for determining the extent of disease and guiding treatment options. The FIGO staging system is commonly used, ranging from Stage I (localized) to Stage IV (distant metastasis). CA-125 is a tumor marker frequently utilized in monitoring treatment response and disease recurrence. Surgical approaches, including oophorectomy (removal of the ovary) and debulking surgery, are often employed as part of the treatment regimen, sometimes in conjunction with chemotherapy. Accurate coding of C56.2 is essential for appropriate treatment planning and reimbursement.
Detailed surgical reports, pathology results, imaging studies, and CA-125 levels.
Diagnosis and treatment planning for ovarian cancer, management of chemotherapy side effects, and follow-up care.
Ensure accurate staging and documentation of treatment response, including any recurrence.
Comprehensive imaging reports detailing findings related to ovarian masses.
Imaging for suspected ovarian tumors, follow-up imaging for treatment response.
Clear documentation of imaging techniques and findings to support diagnosis.
Performed for treatment of malignant neoplasm of the left ovary.
Operative report detailing the procedure and findings.
Ensure that the surgical approach and any complications are documented.
CA-125 is a tumor marker that can help in diagnosing ovarian cancer, monitoring treatment response, and detecting recurrence. Elevated levels may indicate the presence of malignancy, but they are not definitive on their own.
